ZA896149B - Pharmaceutical formulation for the treatment of diabetes mellitus - Google Patents

Pharmaceutical formulation for the treatment of diabetes mellitus

Info

Publication number
ZA896149B
ZA896149B ZA896149A ZA896149A ZA896149B ZA 896149 B ZA896149 B ZA 896149B ZA 896149 A ZA896149 A ZA 896149A ZA 896149 A ZA896149 A ZA 896149A ZA 896149 B ZA896149 B ZA 896149B
Authority
ZA
South Africa
Prior art keywords
treatment
diabetes mellitus
arg
insulin
pharmaceutical formulation
Prior art date
Application number
ZA896149A
Other languages
English (en)
Inventor
Michael Boerschug
Boerschug Michael
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA896149B publication Critical patent/ZA896149B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA896149A 1988-08-13 1989-08-11 Pharmaceutical formulation for the treatment of diabetes mellitus ZA896149B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3827533A DE3827533A1 (de) 1988-08-13 1988-08-13 Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Publications (1)

Publication Number Publication Date
ZA896149B true ZA896149B (en) 1990-04-25

Family

ID=6360797

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA896149A ZA896149B (en) 1988-08-13 1989-08-11 Pharmaceutical formulation for the treatment of diabetes mellitus

Country Status (18)

Country Link
US (1) US5177058A (enExample)
EP (1) EP0357978B1 (enExample)
JP (1) JPH02101022A (enExample)
KR (1) KR900002801A (enExample)
AT (1) ATE75945T1 (enExample)
AU (1) AU621648B2 (enExample)
CA (1) CA1332354C (enExample)
DE (2) DE3827533A1 (enExample)
DK (1) DK395689A (enExample)
ES (1) ES2039773T3 (enExample)
FI (1) FI95202C (enExample)
GR (1) GR3005326T3 (enExample)
HU (1) HU203670B (enExample)
IE (1) IE61266B1 (enExample)
NO (1) NO178914C (enExample)
NZ (1) NZ230280A (enExample)
PT (1) PT91420B (enExample)
ZA (1) ZA896149B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE4024434A1 (de) * 1990-08-01 1992-02-13 Fresenius Ag Vorrichtung zur ultrafiltrationskontrolle bzw. ultrafiltrationsregelung bei blutreinigungsverfahren
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
ES2218622T3 (es) * 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20050014679A1 (en) * 2001-12-20 2005-01-20 Beals John Michael Insulin molecule having protracted time action
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2518776A1 (en) * 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
CN101389650B (zh) * 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
CN101939023B (zh) * 2007-10-16 2016-08-03 百康有限公司 可经口给药的固体药物组合物及其方法
BRPI0920881B1 (pt) 2008-10-17 2021-09-21 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー/エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー/エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
BR112017012406A2 (pt) 2014-12-12 2018-07-31 Sanofi Aventis Deutschland formulação com relação fixa de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3996679B1 (en) 2019-07-12 2023-09-06 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143591A (en) * 1936-09-26 1939-01-10 Univ Alberta Therapeutic preparation and process of making and using it
US2354211A (en) * 1940-07-02 1944-07-25 Burroughs Wellcome Co Insulin preparation
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3334407A1 (de) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider

Also Published As

Publication number Publication date
JPH02101022A (ja) 1990-04-12
EP0357978A1 (de) 1990-03-14
DK395689D0 (da) 1989-08-11
ATE75945T1 (de) 1992-05-15
GR3005326T3 (enExample) 1993-05-24
IE892594L (en) 1990-02-13
US5177058A (en) 1993-01-05
PT91420A (pt) 1990-03-08
DE58901401D1 (de) 1992-06-17
HUT50443A (en) 1990-02-28
FI95202C (fi) 1996-01-10
FI893783L (fi) 1990-02-14
NO178914B (no) 1996-03-25
AU621648B2 (en) 1992-03-19
FI893783A0 (fi) 1989-08-10
KR900002801A (ko) 1990-03-23
PT91420B (pt) 1995-05-04
EP0357978B1 (de) 1992-05-13
CA1332354C (en) 1994-10-11
FI95202B (fi) 1995-09-29
ES2039773T3 (es) 1996-07-16
NZ230280A (en) 1991-09-25
AU3951489A (en) 1990-02-15
NO893239L (no) 1990-02-14
DE3827533A1 (de) 1990-02-15
IE61266B1 (en) 1994-10-19
HU203670B (en) 1991-09-30
NO178914C (no) 1996-07-03
DK395689A (da) 1990-02-14
NO893239D0 (no) 1989-08-11

Similar Documents

Publication Publication Date Title
GR3005326T3 (enExample)
EP0552256A4 (enExample)
DE3468323D1 (en) Pharmaceutical formulation for the treatment of diabetes mellitus
GB9316895D0 (en) Hepatoselective insulin analogues
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
DK642587A (da) Insulinpraeparat
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
GR3006815T3 (enExample)
AU7284098A (en) Method for preventing gastritis using amylin or amylin agonists
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
AU8687391A (en) Lithium treatment
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
IT1259140B (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina